Stelara Biosimilar Otulfi Approved by FDA to Treat Multiple Autoimmune Disorders
Otulfi is the fourth Stelara biosimilar to be approved by the FDA.
pills © Geekminds - stock.adobe.com
The FDA has approved Stelara biosimilar Otulfi (ustekinumab-aauz) to treat Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis, according to the details of a recent press release. Otulfi is set to launch in the United States or before Feb. 22, 2025. It will be available in subcutaneous and intravenous formulations for adults and children ages six and older. Approval was granted simultaneously in the European Union.
This approval is the result of a global commercialization partnership between biopharmaceutical companies Fresenius Kabi and Formycon.
“The U.S. approval is an important step on our path to sustainable profitability, since FYB202 will contribute strongly to the financial strength of Formycon,” Enno Spillner, chief financial officer of Formycon AG, said in a statement. “We are pleased that with the recent approval decisions of the European Commission and the FDA, we have now successfully completed the formal approval process of FYB202 for the major markets.”
Otulfi is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 responsible for the inflammation seen in autoimmune diseases.
Dosages for Otulfi are weight-based. Subcutaneous injections are available in 45 mg/0.5 mL or 90 mg/mL solutions in a single-dose prefilled syringe and intravenous infusions are available in 130 mg/26 mL (5 mg/mL) single-dose vials.
At least 3% of patients from each indication had one or more adverse reactions including:
- nasopharyngitis
- upper respiratory tract infection
- headache
- fatigue
- vomiting
- urinary tract infection
- injection site erythema
- vulvovaginal candidiasis
- bronchitis
- pruritus
- urinary tract infection
- sinusitis
Reference ustekinumab was originally approved by the FDA in 2009. Wezlana (ustekinumab-auub) was approved last October. Selarsdi (ustekinumab-aekn) was approved in April 2024 and Pyzchiva (ustekinumab-ttwe) was greenlit in June 2024.
Pricing information for Otulfi will be available closer to launch.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
